Major depressive disorder (MDD) is a complex neuropsychiatric disorder and a heterogeneous psychiatric disease with high suicide risk, discussed here as an example condition in multi-omics biomarker research and psychiatric stratification. It is characterized by polygenic architecture, with genome wide association studies reporting thousands of small-effect variants, and by epigenetic contributions alongside brain and blood biomarkers. In the reviewed literature, MDD is also linked to disrupted energy metabolism and gut microbiota changes, including regulation by gut microbiota and metabolite-mediated effects involving dorea formicigenerans. Clinically, it appears as the primary diagnosis in treatment-resistant depression studies, including psilocybin-assisted psychotherapy trials. Recent work also highlights microbiome-based intervention, where autologous fecal microbiota transplantation ameliorated depression-like behaviors in a chronic social defeat stress model.
Biomarkers and disease architecture
- A 2026 systematic review in JAMA Psychiatry emphasized that MDD is a heterogeneous neuropsychiatric disease with high suicide risk and highlighted brain and blood biomarkers, polygenic architecture, and epigenetic contributions (PMID:41739484).
- Multi-omics biomarker research framed MDD as a complex psychiatric disorder suitable for diagnosis and stratification approaches (PMID:41655615).
- GWAS evidence indicates MDD is polygenic, with thousands of small-effect variants contributing to risk (PMID:41739484).
- Brain and blood biomarker findings were synthesized as part of efforts to improve diagnosis and stratification in psychiatric disorders, including MDD (PMID:41655615; PMID:41739484).
Metabolism and gut microbiota
- A 2026 Gut Microbes study linked depressive behavior to disrupted host energy metabolism and gut microbiota remodeling in depressive disorder/MDD (PMID:42023591).
- Gut microbiota was investigated as a regulator contributing to depression in MDD, supporting a microbiome–brain axis mechanism (PMID:42023591).
- dorea formicigenerans was associated with metabolites mediating depressive symptoms, suggesting a specific microbial-metabolic pathway (PMID:42023591).
- autologous fecal microbiota transplantation ameliorated depression-like behaviors in a chronic social defeat stress model, supporting a causal role for microbiota modulation (PMID:42023591).
Clinical studies and treatment context
- In a 2026 Journal of Affective Disorders trial, MDD was the primary diagnosis among participants receiving psilocybin-assisted psychotherapy for anhedonia in treatment-resistant depression (PMID:41690631).
- The trial context underscores MDD’s relevance in interventional psychiatry and symptom-targeted treatment research, especially for anhedonia (PMID:41690631).
- The presence of MDD as a primary condition in clinical enrollment highlights its use as a core diagnostic category in therapeutic studies (PMID:41690631).